ArticleBiomolecules2023
Intestinal Barrier in Post-
Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Plasma Zonulin as a Biomarker of Divergent Channels Latency in Systemic Lupus Erythematosus?Healthcare (Basel, Switzerland) · 2026Article
- Impact of different stress paradigms on irritable bowel syndrome: Evidence from clinical and animal studies.The Journal of international medical research · 2026Review
- Associations between early life exposure to parvovirus and antibiotic treatment and the occurrence and severity of later chronic enteropathy in dogs.The Veterinary record · 2026Article
- Impact of Isoquinoline Alkaloids on the Intestinal Barrier in a Colonic Model ofInternational journal of molecular sciences · 2025Article
- Association of Gut Microbiota With Performance Level Among Iranian Professional and Semi-Professional Runners: A Cross-Sectional Study.Health science reports · 2025Article
- Resistant Starch and Microbiota-Derived Secondary Metabolites: A Focus on Postbiotic Pathways in Gut Health and Irritable Bowel Syndrome.International journal of molecular sciences · 2025Review
- Therapeutic and protective approaches to combatFrontiers in pharmacology · 2025Review
- Transcriptome-wide N6-methyladenosinem modifications analysis of chicken cecum in responding toFrontiers in immunology · 2025Article
- Sex-dependent alterations of colonic epithelial permeability: relevance to irritable bowel syndrome.Frontiers in physiology · 2025Article
- Carvacrol prophylaxis improves clinical outcome and dampens apoptotic and pro-inflammatory immune responses upon Campylobacter jejuni infection of human microbiota-associated IL-10-/- mice.European journal of microbiology & immunology · 2024Article
- Menthol Pretreatment AlleviatesBiomolecules · 2024Article
- Prophylactic Oral Application of Activated Charcoal Mitigates Acute Campylobacteriosis in Human Gut Microbiota-Associated IL-10Biomolecules · 2024Article
- Oral treatment of human gut microbiota associated IL-10Frontiers in microbiology · 2024Article
- Article
- Gut Dysbiosis in Irritable Bowel Syndrome: A Narrative Review on Correlation with Disease Subtypes and Novel Therapeutic Implications.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsWe identified patients with persistent PI-IBS symptoms after
resultsIn PI-IBS, the epithelial resistance of the colon epithelium was unaltered, reflecting an intact paracellular pathway. In contrast, temperature-dependent horseradish peroxidase (HRP, 44 kDa) permeation increased. Short-circuit current (Isc) reflecting active anion secretion and ENaC-dependent electrogenic sodium absorption was unaffected. Early endosome antigen-1 (EEA1) and IL-4 levels increased.
conclusionsIn PI-IBS after
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.